Torley Helen: insider trades.
Torley Helen reported 27 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 20 sales ($12.9M), across 1 company.
- Transactions
- 27
- Purchases (P)
- 0
- Sales (S)
- 20
- Companies
- 1
- Name as filed
- Torley Helen
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | Director, Officer · PRESIDENT AND CEO | 27 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-11 | Halozyme Therapeutics, Inc. | S | 4,508 | $107.55 | 767,780 | Form 4 |
| 2026-09-11 | Halozyme Therapeutics, Inc. | S | 15,492 | $107.15 | 772,288 | Form 4 |
| 2026-09-11 | Halozyme Therapeutics, Inc. | M | 20,000 | $18.41 | 787,780 | Form 4 |
| 2026-09-10 | Halozyme Therapeutics, Inc. | M | 20,000 | $18.41 | 787,780 | Form 4 |
| 2026-09-10 | Halozyme Therapeutics, Inc. | S | 14,588 | $107.01 | 773,192 | Form 4 |
| 2026-09-10 | Halozyme Therapeutics, Inc. | S | 5,412 | $107.58 | 767,780 | Form 4 |
| 2026-09-09 | Halozyme Therapeutics, Inc. | S | 100 | $108.67 | 767,780 | Form 4 |
| 2026-09-09 | Halozyme Therapeutics, Inc. | S | 6,596 | $107.82 | 767,880 | Form 4 |
| 2026-09-09 | Halozyme Therapeutics, Inc. | M | 20,000 | $18.41 | 787,780 | Form 4 |
| 2026-09-09 | Halozyme Therapeutics, Inc. | S | 13,304 | $107.22 | 774,476 | Form 4 |
| 2026-08-19 | Halozyme Therapeutics, Inc. | M | 20,000 | $18.41 | 787,780 | Form 4 |
| 2026-08-19 | Halozyme Therapeutics, Inc. | S | 7,200 | $106.36 | 780,580 | Form 4 |
| 2026-08-19 | Halozyme Therapeutics, Inc. | S | 9,600 | $107.22 | 770,980 | Form 4 |
| 2026-08-19 | Halozyme Therapeutics, Inc. | S | 3,200 | $107.77 | 767,780 | Form 4 |
| 2026-08-18 | Halozyme Therapeutics, Inc. | M | 20,000 | $18.41 | 787,780 | Form 4 |
| 2026-08-18 | Halozyme Therapeutics, Inc. | S | 5,703 | $103.08 | 782,077 | Form 4 |
| 2026-08-18 | Halozyme Therapeutics, Inc. | S | 4,897 | $104.11 | 777,180 | Form 4 |
| 2026-08-18 | Halozyme Therapeutics, Inc. | S | 9,400 | $104.87 | 767,780 | Form 4 |
| 2026-08-17 | Halozyme Therapeutics, Inc. | S | 7,500 | $103.48 | 767,780 | Form 4 |
| 2026-08-17 | Halozyme Therapeutics, Inc. | S | 9,000 | $102.55 | 775,280 | Form 4 |
| 2026-08-17 | Halozyme Therapeutics, Inc. | S | 2,100 | $101.77 | 784,280 | Form 4 |
| 2026-08-17 | Halozyme Therapeutics, Inc. | S | 500 | $100.46 | 786,380 | Form 4 |
| 2026-08-17 | Halozyme Therapeutics, Inc. | M | 20,000 | $18.41 | 787,780 | Form 4 |
| 2026-08-17 | Halozyme Therapeutics, Inc. | S | 900 | $98.96 | 786,880 | Form 4 |
| 2026-07-08 | Halozyme Therapeutics, Inc. | M | 1,923 | $12.07 | 769,703 | Form 4 |
| 2026-07-08 | Halozyme Therapeutics, Inc. | S | 888 | $79.28 | 768,815 | Form 4 |
| 2026-07-08 | Halozyme Therapeutics, Inc. | S | 1,035 | $80.19 | 767,780 | Form 4 |
Questions
What stock did Torley Helen buy or sell?
Torley Helen reported 27 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 20 sales ($12.9M), across 1 company.
Is Torley Helen the same person as other filers with this name?
This page covers SEC CIK 1528185 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/torley-helen-1528185.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.